Coagulation Disorders in Liver Disease

2002 ◽  
Vol 22 (1) ◽  
pp. 083-096 ◽  
Author(s):  
Lucio Amitrano ◽  
Maria A. Guardascione ◽  
Vincenzo Brancaccio ◽  
Antonio Balzano
Keyword(s):  
Liver Disease ◽  
Coagulation Disorders

scholarly journals Coagulation disorders and hemostasis in liver disease: Pathophysiology and critical assessment of current management

Hepatology ◽  
2006 ◽  
Vol 44 (4) ◽  
pp. 1039-1046 ◽  
Author(s):  
Stephen H. Caldwell ◽  
Maureane Hoffman ◽  
Ton Lisman ◽  
B. Gail Macik ◽  
Patrick G. Northup ◽  
...  
Keyword(s):  
Liver Disease ◽  
Critical Assessment ◽  
Coagulation Disorders ◽  
Current Management

Improvement Of Plasmatic Coagulation In Patients With Liver Disease To Enable Necessary Diagnostic And Therapeutic Steps

1981 ◽  
Author(s):  
G E Vogel ◽  
S Tuchtenhagen ◽  
Ch Komm ◽  
A Oberdorfer
Keyword(s):  
Liver Disease ◽  
Esophageal Varices ◽  
Liver Diseases ◽  
Bleeding Complication ◽  
Coagulation Factors ◽  
Coagulation Disorders ◽  
Chromogenic Substrates ◽  
At Iii ◽  
Plasmatic Coagulation ◽  
Plasma Activity

Specific plasmatic concentrations of coagulation factors are necessary in endoscopic treatment e.g. slerosis of esophageal varices. Thrombotest of 35 to 40% is necessar. To correct with factor concentrates and fibrinogen is dangerous in cause of pushing DIC (disseminated intravascular coagulation). The substitution of the inhibitor AT III which is succeeded from prothrombin concentrates and fibrinogen avoid fearful consumption reactions. The AT III plasma activity was measured by chromogenic substrates in citric plasma. In 5 patients (2 female, 3 male- age 19-67) the diminished AT III-levels were increased to the normal value of 80%. After normalization of the inhibitors prothrombin complexes and if necessary fibrinogen were substituted. It was seen an assessable improvement of the plasmatic coagulation which depends on the unit concentration of the substituted factors. In the improved coagulation situation 2 laparoscopies and 3 slerosis of esophageal varices could be done without any bleeding complication.Patients with liver diseases and coagulation disorders who were unsuitable for endoscopic and surgical treatment can be treated with this concept.

scholarly journals Thrombin Generation in Chronic Liver Diseases—A Pilot Study

Healthcare ◽  
2021 ◽  
Vol 9 (5) ◽  
pp. 550
Author(s):  
Liliana Vecerzan ◽  
Ariela Olteanu ◽  
Ionela Maniu ◽  
Adrian Boicean ◽  
Călin Remus Cipăian ◽  
...  
Keyword(s):  
Liver Disease ◽  
Pilot Study ◽  
Chronic Liver Disease ◽  
Liver Diseases ◽  
Thrombin Generation ◽  
Chronic Liver ◽  
Control Group ◽  
Coagulation Disorders ◽  
Chronic Liver Diseases ◽  
Control Subjects

The knowledge about coagulation disorders in patients with chronic liver disease changed in the last decade. The aim of this study was to analyze the parameters of thrombin generation in patients with chronic liver disease, as they are the most appropriate biomarkers to explore coagulation. (1) Background: The knowledge about coagulation disorders in patients with chronic liver disease changed in the last decade. The study of thrombin generation in patients with chronic liver disease provides a much more accurate assessment of the coagulation cascade; (2) Methods: This study is a prospective observational pilot study on hospitalized patients with chronic liver diseases that analyzed thrombin generation performed from their platelet-poor plasma versus that of control subjects. We analyzed a group of 59 patients with chronic liver disease and 62 control subjects; (3) Results: Thrombin generation was lower in hepatitis and cirrhosis patients compared to controls and decreases as the disease progressed. Lag time was higher in ethanolic etiology compared to the control group. Peak thrombin and endogenous thrombin potential were shorter in all etiologies when compared to the control group. The velocity index was significantly lower in HCV hepatopathies, ethanolic, and mixed etiology when compared with normal individuals; (4) Conclusions: Given the variability of thrombin generation in patients with chronic liver disease, its assay could serve to identify patients with high thrombotic and hemorrhagic risk and establish personalized conduct toward them.

Liver Disease; Hemostasis and Coagulation Disorders

2020 ◽  
pp. 418-428
Author(s):  
Emmanuelle de Raucourt ◽  
Dominique Valla ◽  
Pierre-Emmanuel Rautou
Keyword(s):  
Liver Disease ◽  
Coagulation Disorders
Sign in / Sign up

Export Citation Format

Share Document